Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopause
Effect of Hyperbaric Oxygen Therapy on Insulin Resistance in Postmenopausal Women
Cairo University
40 participants
Jan 28, 2025
INTERVENTIONAL
Conditions
Summary
Background: In postmenopausal females, Insulin resistance is commonly encountered in clinical setting. Hyperbaric oxygen therapy have been proposed effective in lowering blood glucose level and improving function. Identification of clinical examination variables as predictors to blood glucose levels and dysfunction would offer therapists the chance to undertake clinical decisions and consequently improve treatment efficiency. Objectives: This Predictive validity, diagnostic study conduct to examine the effect of hyperbaric oxygen therapy on insulin resistance in postmenopausal women.
Eligibility
Inclusion Criteria8
- All females were clinically diagnosed with Postmenopausal Insulin resistance.
- Their ages were ranged from 55-65 years old.
- Their BMI was 30-34.9 kg/m².
- All patients should had controlled blood glucose levels by oral hypoglycemic drugs.
- All patients should had cardiac Ejection Fraction >or =50%.
- Their Chest X-ray reported normal.
- Their Ear ,nose , thorax will be clinically evaluated by a specialized ENT physician to ensure fitting for hyperbaric chamber
- Voluntary acceptance of participation in the study .
Exclusion Criteria7
- Participants will be excluded if they have :
- Chronic obstructive pulmonary disease.
- Cardiac pacemakers.
- Epileptic fits.
- Physically disable .
- Any disorder that lead to ulcers other than diabetes such as ahistory of chronic peripheral arterial disease.
- \-
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Hyperbaric Oxygen Therapy (HBOT):(Haux, Starmed 2300, Germany). A multichamper Double-lock, divided into Main chamber and Antichamber, with omega Ω-shape and all safety and CE-Certificate,
Metformin reduces serum glucose level by several different mechanisms without increasing insulin secretion.it increases the effects of insulin so it is termed "insulin sensitizer ,metformin also suppresses the endogenous glucose production by the liver ,which is mainly due to a reduction in the rate of gluconeogenesis and asmall effect on glycogenolysis. Moreover, metformin activates the enzyme adenosine monophosphate kinase (AMPK) resulting in the inhibition of key enzymes involved in gluconeogenesis and glycogen synthesis in the liver while stimulating insulin signaling and glucose transport in muscles
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06806345